Asset Management One Co. Ltd. Has $300.76 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Asset Management One Co. Ltd. grew its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 364,151 shares of the company's stock after buying an additional 23,879 shares during the period. Eli Lilly and Company accounts for about 1.0% of Asset Management One Co. Ltd.'s portfolio, making the stock its 16th biggest holding. Asset Management One Co. Ltd.'s holdings in Eli Lilly and Company were worth $300,756,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in LLY. Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $43,000. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $48,000. Highline Wealth Partners LLC boosted its stake in Eli Lilly and Company by 53.3% in the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after purchasing an additional 24 shares during the period. Capital A Wealth Management LLC bought a new position in Eli Lilly and Company during the 4th quarter worth $63,000. Finally, Bellwether Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $66,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $14.33 during mid-day trading on Wednesday, hitting $792.41. 3,019,948 shares of the stock traded hands, compared to its average volume of 3,666,831. The firm has a 50 day simple moving average of $781.26 and a two-hundred day simple moving average of $800.21. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The company has a market cap of $751.00 billion, a PE ratio of 64.48, a price-to-earnings-growth ratio of 1.13 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.58 earnings per share. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. Eli Lilly and Company's payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, June 7th. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Finally, Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.